ADVFN - Advanced Financial Network.
HOME» NASDAQ » M » MYL Stock Price » MYL Stock News

Mylan Inc. Share News

 Mylan Inc. (mm) Stock Price
MYL Stock Price
 Mylan Inc. (mm) Stock Chart
MYL Stock Chart
 Mylan Inc. (mm) Stock News
MYL Stock News
 Mylan Inc. (mm) Company Information
MYL Company Information
 Mylan Inc. (mm) Stock Trades
MYL Stock Trades

Mylan Confirms Endo Suit Over Generic Migraine Drug Application

DOW JONES NEWSWIRES Mylan Inc. (MYL) confirmed Wednesday that it has been sued by Endo Pharmaceuticals Holdings Inc. (ENDP) over its application for approval of a generic drug used to treat acute migraine headaches in adults. Mylan--one of the world's largest generic drug makers--said it believes it is the first company to file a substantially complete application for approval of frovatriptan succinate EQ, a generic version of Frova. The company said it expects to qualify for 180 days of marketing exclusivity upon final approval from the Food and Drug Administration. Mylan, which has had litigation-related charges figure prominently in its recent quarterly results, last month reported second-quarter earnings surged 70% as sales got a lift from a weaker dollar. Shares closed Tuesday at $20.01 and were inactive in recent premarket trade. Through the latest close, the stock is down 5.3% since the start of the year. -By Mia Lamar, Dow Jones Newswires; 212-416-3207; mia.lamar@dowjones.com

Stock News for Mylan Inc. (MYL)
DateTimeHeadline
08/28/201515:15:05Registration Statement for Securities to Be Issued in Business...
08/28/201508:20:00Mylan Holders Approve Perrigo Purchase
08/28/201508:03:00Perrigo Confident Its Shareholders Will Reject Mylan's Value...
08/28/201507:21:00Mylan Shareholders Overwhelmingly Approve Proposed Acquisition...
08/25/201514:59:00Mylan Confirms the U.S. Patent and Trademark Office Institutes...
08/25/201514:13:00Mylan Launches Generic Zosyn® Injection
08/25/201513:20:00Mylan Comments on Misleading Statements Made by Perrigo
08/21/201515:19:00Mylan Clarifies Certain Inaccuracies by Third Parties Related...
08/20/201517:06:39Additional Proxy Soliciting Materials (definitive) (defa14a)
08/20/201517:03:39Additional Proxy Soliciting Materials (definitive) (defa14a)
08/18/201511:31:00Mylan Statement in Response to FDA Warning Letter Relating to...
08/18/201507:30:00Mylan Confirms First-to-File Patent Challenge Relating to Zytiga®
08/14/201513:30:00Paulson & Co. Votes in Support of Mylan's Proposed Merger with...
08/14/201511:07:00ISS Affirms Perrigo's Position That Proposed Mylan Transaction...
08/14/201509:18:00Mylan Responds to ISS Recommendation Regarding Perrigo Transaction
08/14/201509:00:51Proxy Adviser Says Mylan Holders Should Shun Perrigo Deal
08/14/201508:50:00Additional Proxy Soliciting Materials (definitive) (defa14a)
08/13/201507:00:00Mylan Lowers Acceptance Condition on Perrigo Offer to Greater...
08/12/201515:01:00Mylan and Disney Team Up to Bring New Resources to Life for Families...
08/12/201514:09:00Egan-Jones Joins Glass Lewis in Recommending Mylan Shareholders...

Mylan Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad